Genscript Biotech’s subsidiary Legend Biotech, which agreed to an investment worth nearly $151m from Eli Lilly and Johnson & Johnson last month, has filed to go public.

Legend Biotech, a cellular therapy subsidiary of China-based biotech producer Genscript Biotech, filed to go public on Wednesday with a placeholder amount of $100m. The company has applied for a listing on the Nasdaq Global Market, though it has not yet determined how many American Depositary Shares it will issue, or at what price. Formed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.